Wave Life Sciences Submits 1st Trial Application for First-ever RNA Editing Clinical Candidate

 WVE-006 is the first-ever RNA editing program to enter clinical development and is designed to restore production and circulation of functional, wild-type alpha-1 antitrypsin (AAT) protein and reduce levels of mutant Z-AAT protein, thereby addressing alpha-1 antitrypsin deficiency-related lung disease, liver disease or both

Wave expects to initiate dosing in the first-in-human clinical program in 4Q 2023 and deliver AAT protein restoration data from AATD patients treated with WVE-006 in 2024

Under its collaboration with GSK, Wave is eligible to receive substantial milestone payments for WVE-006 in 2023 and beyond

Wave plans to host a virtual “R&D Day” on September 28, 2023; topics to include the WVE-006 clinical program and how Wave is extending its leadership in RNA editing with additional programs

https://www.biospace.com/article/releases/wave-life-sciences-announces-submission-of-first-clinical-trial-application-for-wve-006-the-first-ever-rna-editing-clinical-candidate-and-plans-for-upcoming-virtual-r-and-d-day-/